Publications
A qualitative exploration of unintentional vs. intentional exposure to fentanyl among people who use drugs in Austin, Texas.
J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.10.005
Cance JD, Bingaman A, Kane H, Hairgrove S, Torrez SB, Buck A, Zagorski CM, Loera LJ, Hill LG.
A wound care and immunization needs assessment for participants of a mobile syringe services program in Austin, Texas.
J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.10.018
Britton TR, Clague MR, Zagorski CM, Hill LG, Loera LJ.
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states
Drug Alcohol Depend. 2022. DOI: 0.1016/j.drugalcdep.2022.109518.
Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel HN, Peckham AM, Chen C, Ganetsky VS, Yeung MS, Zagorski CM, Reveles KR.
Description and Evaluation of a Pilot Advanced Pharmacy Practice Experience in Addiction Medicine
Am J Pharm Educ. 2022. DOI: 10.5688/ajpe8926
Loera LJ, Hill LG, Zagorski CM, Jermain ML, Tirado CF.
Increasingly powerful opioid antagonists are not necessary
Int J Drug Policy. 2022. DOI: 10.1016/j.drugpo.2021.103457.
Hill LG, Zagorski CM, Loera LJ.
Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice
Subst Abus. 2022. DOI: 10.1080/08897077.2022.2060423.
Gugala E, Briggs O, Moczygemba LR, Brown CM, Hill LG.
Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review.
Subst Abus. 2022. DOI: 10.1080/08897077.2021.2010161
White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA
Addiction. 2021. DOI: 10.1111/add.15314
Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR.
Considering the potential benefits of over-the-counter naloxone
Integr Pharm Res Pract. 2021. DOI: 10.2147/iprp.S244709
Evoy KE, Hill LG, Davis CS.
Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19
Am J Health Syst Pharm. 2021. DOI: 10.1093/ajhp/zxab003
Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH.